William Bindley Sells 3,570,677 Shares of Guardian Pharmacy Services (NYSE:GRDN) Stock

Guardian Pharmacy Services, Inc. (NYSE:GRDN) Director William Bindley sold 3,570,677 shares of Guardian Pharmacy Services stock in a transaction that occurred on Friday, March 20th. The shares were sold at an average price of $29.68, for a total transaction of $105,977,693.36. Following the transaction, the director owned 4,469,316 shares of the company’s stock, valued at $132,649,298.88. The trade was a 44.41% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Guardian Pharmacy Services Stock Down 3.0%

Guardian Pharmacy Services stock opened at $35.41 on Friday. Guardian Pharmacy Services, Inc. has a twelve month low of $19.17 and a twelve month high of $38.12. The company has a market capitalization of $2.24 billion, a P/E ratio of 45.98 and a beta of 0.86. The stock’s 50 day moving average is $32.74 and its 200 day moving average is $29.91.

Guardian Pharmacy Services (NYSE:GRDN) last announced its quarterly earnings data on Wednesday, March 11th. The company reported $0.37 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.10. Guardian Pharmacy Services had a return on equity of 31.64% and a net margin of 3.40%.The business had revenue of $397.62 million during the quarter, compared to analysts’ expectations of $390.04 million. The business’s revenue was up 17.4% compared to the same quarter last year. As a group, equities analysts expect that Guardian Pharmacy Services, Inc. will post 0.87 EPS for the current year.

Key Guardian Pharmacy Services News

Here are the key news stories impacting Guardian Pharmacy Services this week:

• Positive Sentiment: Q3 / latest quarter: GRDN beat EPS and revenue estimates (revenue +17.4% YoY), which supports growth expectations. MarketBeat GRDN summary
• Positive Sentiment: Analyst momentum: several firms (Truist, Raymond James, Oppenheimer, Stephens, Zacks) have raised targets or ratings recently, leaving a buy/strong-buy consensus and a ~$38 average target. Analyst coverage
• Neutral Sentiment: Institutional holders: several funds (Vanguard, Wellington, Brown Advisory, Franklin, Valiant) have recently adjusted positions; this shows continuing institutional interest but mixed flows. Holders data
• Neutral Sentiment: Market writeups flagged “major insider exodus,” useful for context but not new filings by itself. TipRanks article
• Negative Sentiment: Director Thomas J. Salentine, Jr. sold 3,570,677 shares at ~$29.68 (~$106.0M), a ~44% reduction — a large block that likely pressured the stock. SEC filing
• Negative Sentiment: Director William E. Bindley sold 3,570,677 shares at ~$29.68 (~$106.0M), a ~44% reduction — another very large director sale. SEC filing
• Negative Sentiment: Director John Ackerman sold 1,103,364 shares at ~$29.68 (~$32.7M), a ~76% reduction in his stake. SEC filing
• Negative Sentiment: Officer Fred Burke sold 671,432 shares at ~$29.68 (~$19.9M), a ~44% cut to his position. SEC filing
• Negative Sentiment: Insider Kendall Forbes sold 346,672 shares at ~$29.68 (~$10.3M), reducing her holding by ~43%. SEC filing
• Negative Sentiment: Insider David K. Morris sold 187,855 shares at ~$29.68 (~$5.6M), cutting his position by ~42%. SEC filing
• Negative Sentiment: Major shareholder Equity Fund L.P. (Cardinal) sold 275,728 shares at ~$29.68 (~$8.2M), a ~44% stake reduction — signals significant institutional unloading. SEC filing

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the stock. Rakuten Investment Management Inc. purchased a new stake in Guardian Pharmacy Services during the 3rd quarter valued at $433,000. Geode Capital Management LLC lifted its holdings in shares of Guardian Pharmacy Services by 65.9% during the 2nd quarter. Geode Capital Management LLC now owns 336,701 shares of the company’s stock valued at $7,177,000 after buying an additional 133,715 shares during the period. CSM Advisors LLC boosted its stake in shares of Guardian Pharmacy Services by 40.9% in the 3rd quarter. CSM Advisors LLC now owns 135,665 shares of the company’s stock worth $3,559,000 after buying an additional 39,360 shares during the last quarter. TimesSquare Capital Management LLC boosted its stake in shares of Guardian Pharmacy Services by 5.6% in the 3rd quarter. TimesSquare Capital Management LLC now owns 860,173 shares of the company’s stock worth $22,562,000 after buying an additional 45,950 shares during the last quarter. Finally, Aristotle Capital Boston LLC grew its holdings in shares of Guardian Pharmacy Services by 58.5% in the third quarter. Aristotle Capital Boston LLC now owns 649,463 shares of the company’s stock worth $17,035,000 after acquiring an additional 239,790 shares during the period.

Analyst Ratings Changes

Several analysts recently commented on the stock. Weiss Ratings reissued a “hold (c+)” rating on shares of Guardian Pharmacy Services in a research report on Monday, December 29th. Oppenheimer upped their target price on shares of Guardian Pharmacy Services from $35.00 to $38.00 and gave the stock an “outperform” rating in a research note on Thursday, March 12th. Raymond James Financial reiterated an “outperform” rating and set a $40.00 price target on shares of Guardian Pharmacy Services in a report on Thursday, March 12th. Zacks Research raised shares of Guardian Pharmacy Services from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, March 18th. Finally, Stephens boosted their price objective on shares of Guardian Pharmacy Services from $35.00 to $36.00 and gave the stock an “overweight” rating in a report on Wednesday, January 14th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and an average target price of $38.00.

About Guardian Pharmacy Services

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.